A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : Cmax

Search Conditions:
Search Keyword : Cmax
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: Cmax
Appearance Frequency: 230 time(s)
Long forms: 146

Display Settings:
[Display Entries]
Long Form, 100 entries
    (Appearance freq, Descending)
Long Form, all entries
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
curve, maximum concentration
(34 times)
Pharmacology
(15 times)
tmax (5 times)
AUC (4 times)
PK (4 times)
1987 Pharmacokinetics and pharmacodynamics of two formulations of verapamil.
maximum concentration
(24 times)
Pharmacology
(14 times)
AUC (7 times)
Tmax (4 times)
AEs (2 times)
1990 Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects.
concentration maximum
(15 times)
Reproductive Medicine
(3 times)
Tmax (6 times)
AUC (4 times)
PK (4 times)
1980 Enzyme inducing effects of phenobarbital on nitrazepam metabolism in dogs.
Compare maximum concentration
(6 times)
Disaster Medicine
(3 times)
HIO (4 times)
ROSC (4 times)
Tmax (4 times)
0 Humerus intraosseous administration of epinephrine in normovolemic and hypovolemic porcine model.
concentration:maximum concentration
(3 times)
Pharmacology
(2 times)
Ae (1 time)
AUC (1 time)
HAI group (1 time)
2005 Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.
calculated, with a peak maximum
(2 times)
Pharmacology
(1 time)
--- 1989 [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
calculation of maximum
(2 times)
Pulmonary Medicine
(1 time)
MDI (1 time)
1997 Effects of airway calibre on lung delivery of nebulised salbutamol.
carbon number maximum
(2 times)
Environmental Health
(2 times)
CPI (1 time)
PAHs (1 time)
TAHs (1 time)
2002 Extractable organic matter in PM10 from LiWan district of Guangzhou City, PR China.
concentration (AUC₀-∞) and maximum blood concentration
(2 times)
Nutritional Sciences
(1 time)
P-gp (2 times)
CI (1 time)
CSP (1 time)
2012 The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
10  curve (AUC(0-infinity)) = 78.33 h x ng/ml, maximum plasma concentration
(2 times)
Pharmacology
(2 times)
MRT (2 times)
PTF (2 times)
tmax (1 time)
2005 Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
11  curve (AUC(0-infinity)), the maximum observed plasma concentration
(2 times)
Medicine
(1 time)
CI (1 time)
GLS (1 time)
tmax (1 time)
2001 Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
12  curve from zero to infinity (AUC(0-infinity)) and maximum plasma concentration
(2 times)
Drug Therapy
(2 times)
--- 1998 Effect of Maalox on the oral absorption of sparfloxacin.
13  area-under-curve (AUC0-24 h) and maximal plasma concentration
(1 time)
Biochemistry
(1 time)
DRN (1 time)
SMEDDS (1 time)
2015 Reduced Food-Effect on Intestinal Absorption of Dronedarone by Self-microemulsifying Drug Delivery System (SMEDDS).
14  CAB maximal plasma concentrations
(1 time)
Endocrinology
(1 time)
AUC (1 time)
CAB (1 time)
1995 Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.
15  calculated and included maximum plasma concentration
(1 time)
Mental Disorders
(1 time)
PK (1 time)
Tmax (1 time)
2013 Pharmacokinetics and Safety of Duloxetine Enteric-coated Tablets in Chinese Healthy Volunteers: A Randomized, Open-label, Single- and Multiple-dose Study.
16  calculated maximum
(1 time)
Veterinary Medicine
(1 time)
--- 1995 Disposition kinetics and bioavailability of piperacillin and cephapirin in mares.
17  can eradicate the persisters at respective maximum serum/plasma concentration
(1 time)
Microbiology
(1 time)
RA (1 time)
2018 The drug tolerant persisters of Riemerella anatipestifer can be eradicated by a combination of two or three antibiotics.
18  capsule and sprinkles were bioequivalent; ratios for maximum concentration
(1 time)
Pediatrics
(1 time)
AUC (1 time)
CI (1 time)
IR (1 time)
2014 Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin()) in healthy adult volunteers.
19  capsule, maximum plasma drug concentration
(1 time)
Veterinary Medicine
(1 time)
i.v (1 time)
p.o (1 time)
SD (1 time)
1997 Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats.
20  carbenicillin, although the maximum concentration
(1 time)
Anti-Bacterial Agents
(1 time)
AUC (1 time)
CSF (1 time)
1981 Comparative pharmacokinetics of ampicillin and carbenicillin in the cerebrospinal fluid of rabbits with staphylococcal meningitis with reference to half-lives and areas under the curve.
21  Carbogen breathing did not affect the maximum peak area
(1 time)
Neoplasms
(1 time)
IF (1 time)
MNU (1 time)
MRS (1 time)
1997 In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas.
22  Caucasians, Southern Asians achieved higher maximum plasma concentration
(1 time)
Pharmacology
(1 time)
AUC (1 time)
CI (1 time)
CYP3A (1 time)
1996 Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity.
23  caused a clear-cut rise in peak serum digoxin levels
(1 time)
Drug Therapy
(1 time)
AUC (1 time)
CLR (1 time)
1984 Influence of amiodarone on oral digoxin bioavailability in healthy volunteers.
24  caused a modest increase in maximum observed concentration
(1 time)
Complementary Therapies
(1 time)
Vss (1 time)
2013 Effects of Lepidium sativum, Nigella sativa and Trigonella foenum-graceum on phenytoin pharmacokinetics in beagle dogs.
25  causes an increase in both the maximum concentration
(1 time)
Psychopharmacology
(1 time)
DDCI (1 time)
LD (1 time)
PD (1 time)
2013 Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
26  CBZ resulted in increased plasma maximum concentration
(1 time)
Biology
(1 time)
CBZ (1 time)
PE (1 time)
RP-HPLC (1 time)
2017 Effects of Paeonia emodi on hepatic cytochrome P450 (CYP3A2 and CYP2C11) expression and pharmacokinetics of carbamazepine in rats.
27  cefoperazone maximal concentration in plasma
(1 time)
Anti-Bacterial Agents
(1 time)
CL (1 time)
Vss (1 time)
1988 Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.
28  cefpodoxime average maximum plasma concentration
(1 time)
Pharmacology
(1 time)
HPLC (1 time)
i.v (1 time)
2007 The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
29  ceftazidime and avibactam, respectively, were as follows: maximum plasma concentration
(1 time)
Anti-Bacterial Agents
(1 time)
AUC0-8 (1 time)
CLss (1 time)
CVVH (1 time)
2017 Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
30  cells maximally relaxed
(1 time)
Drug Therapy
(1 time)
VIP (1 time)
1998 Role of vasoactive intestinal polypeptide in the adaptation of intestinal smooth muscle cells to mechanical distension.
31  centers aim for a maximum serum concentration
(1 time)
Drug Therapy
(1 time)
AUC (1 time)
CF (1 time)
CFF (1 time)
2016 Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.
32  cephaeline maximum concentration
(1 time)
Drug Therapy
(1 time)
AUC (1 time)
SI (1 time)
2000 Single dose pharmacokinetics of syrup of ipecac.
33  cessation, maximum insulin concentration
(1 time)
Endocrinology
(1 time)
AUC (1 time)
2006 The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin.
34  change in insulin maximum concentration
(1 time)
BPA (1 time)
HbA1c (1 time)
HG (1 time)
2018 Experimental BPA Exposure and Glucose-Stimulated Insulin Response in Adult Men and Women.
35  characteristics and maximal drug concentration
(1 time)
Communicable Diseases
(1 time)
RMI (1 time)
2016 Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
36  characteristics, ie, maximum
(1 time)
Drug Therapy
(1 time)
AUC (1 time)
CR (1 time)
PK (1 time)
2007 Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
37  characterized by evaluation of the maximum plasma concentrations
(1 time)
Pharmacology
(1 time)
MAT (1 time)
ME299 (1 time)
MEA (1 time)
1990 Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug.
38  chromatography/mass spectrometry was used to determine a maximum concentration
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
AUCo-t (1 time)
AUCoo (1 time)
TDF (1 time)
2019 Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills.
39  circulation after i.p. administration, with the maximal concentration
(1 time)
Antineoplastic Agents
(1 time)
AC (1 time)
MRT (1 time)
1992 Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
40  citric acid showed a significant higher maximum concentration
(1 time)
Veterinary Medicine
(1 time)
--- 1990 [Effect of citric acid and calcium on the bioavailability of orally-administered oxytetracycline in piglets].
41  clarithromycin resulted in a reduction in darunavir maximum plasma concentration
(1 time)
Pharmacology
(1 time)
--- 2008 Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
42  clearance (by ∼2.5-fold) and decreased maximum plasma concentration
(1 time)
Pharmacokinetics
(1 time)
--- 2016 Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
43  clearance maxima
(1 time)
Chemistry
(1 time)
AUC (1 time)
FITC (1 time)
FP (1 time)
2018 Ex Vivo and in Vivo Study of Sucrosomial Iron Intestinal Absorption and Bioavailability.
44  clinical maximumplasmaconcentration
(1 time)
Pharmacology
(1 time)
HLMs (1 time)
2019 Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes.
45  clomipramine was 0.75-3.1 h, maximum plasma concentration
(1 time)
Pharmacology
(1 time)
Tmax (1 time)
1998 The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine.
46  co-administered agent and reduced the maximal plasma concentration
(1 time)
Antineoplastic Agents
(1 time)
--- 2016 Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.
47  co-administered with DRV/r, the sildenafil maximum plasma concentration
(1 time)
Pharmaceutical Preparations
(1 time)
AUC (1 time)
2008 Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
48  co-administration of rivaroxaban and enalapril, the maximum plasma concentration
(1 time)
Pharmacology
(1 time)
QC (1 time)
RSD (1 time)
2019 Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study.
49  co-administration of tanjin decreased the maximum plasma concentration
(1 time)
Medicine
(1 time)
--- 2019 Pharmacokinetic Drug Interaction Between Rosuvastatin and Tanjin in Healthy Volunteers and Rats.
50  co-administration revealed no significant differences in the maximum concentrations
(1 time)
Drug Therapy
(1 time)
TP (1 time)
1999 Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline.
51  co-administration we observed increased erlotinib maximum concentration
(1 time)
Chemistry
(1 time)
IER (1 time)
2017 Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice.
52  co-administration: for quetiapine, maximal plasma concentration
(1 time)
Drug Therapy
(1 time)
AUC0-infinity (1 time)
CL (1 time)
QTP-H (1 time)
2005 Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia.
53  coadministration, the maximum peak concentration
(1 time)
Pharmacology
(1 time)
--- 1995 Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men.
54  coefficients of variation associated with the maximum plasma concentration
(1 time)
Therapeutics
(1 time)
AUC (1 time)
2001 Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine.
55  coincident with significantly higher maximum
(1 time)
Parasitology
(1 time)
ABSO (1 time)
ABZ (1 time)
AUC (1 time)
1995 The pharmacokinetics of albendazole metabolites following administration of albendazole, albendazole sulfoxide and netobimin to one-month- and eight-month-old sheep.
56  colistin maximum
(1 time)
Pulmonary Medicine
(1 time)
CMS (1 time)
MIC (1 time)
2010 Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
57  combination showed maximum plasma concentration decreased
(1 time)
Pharmacology
(1 time)
AUC (1 time)
DH-HL (1 time)
DH-HQ (1 time)
2008 Anthraquinone pharmacokinetics in Xiexin decoction and the different combinations of its constituent herbs.
58  combination with penbutolol the maximum serum concentration
(1 time)
Drug Therapy
(1 time)
--- 1987 Kinetics of piretanide tablets, penbutolol tablets and the fixed combination of both drugs in healthy male subjects after a single oral dose.
59  combined, and DIF. Maximum concentration
(1 time)
Pharmacology
(1 time)
CIP (1 time)
DIF (1 time)
ENR (1 time)
2000 Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs.
60  commercial tablets, the liposomal formulation enhanced the maximum plasma concentration
(1 time)
Chemistry
(1 time)
OA (1 time)
PVP-K30 (1 time)
PVPOALs (1 time)
2017 Preparation, characterization and in vivo pharmacokinetic study of PVP-modified oleanolic acid liposomes.
61  Comparable mean PN and PL maximum plasma concentrations
(1 time)
Pharmacology
(1 time)
AUC (1 time)
PL (1 time)
PN (1 time)
1988 Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses.
62  comparable values for maximum serum concentration
(1 time)
Pharmacology
(1 time)
AUC (1 time)
HP-beta-CD (1 time)
2012 Pharmacokinetic equivalence of Taxotere and SID530, a novel docetaxel formulation containing hydroxypropyl-beta-cyclodextrin in monkeys.
63  comparable with a similar absorption rate, giving a maximum concentration
(1 time)
Pharmacology
(1 time)
TDS (1 time)
1999 Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems.
64  comparatively low mean maximum plasma levels
(1 time)
Toxicology
(1 time)
AUC (1 time)
1995 Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates.
65  compare bioavailability parameters, such as the maximum observed concentration
(1 time)
Pharmacology
(1 time)
--- 2018 Design and inference for 3-stage bioequivalence testing with serial sampling data.
66  compare bioavailability, maximum concentration
(1 time)
Complementary Therapies
(1 time)
--- 2009 Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system.
67  compare oral vs. vaginal administration for maximum concentration
(1 time)
Reproductive Medicine
(1 time)
Tmax (1 time)
2005 Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration.
68  compare the log-transformed maximum observed serum concentration
(1 time)
Pharmaceutical Preparations
(1 time)
AUClast (1 time)
AUCs (1 time)
CIs (1 time)
2013 Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
69  compared maximal plasma concentrations
(1 time)
Transplantation
(1 time)
LVADs (1 time)
2018 Pharmacokinetics of Sildenafil in Patients with a Left Ventricular Assist Device: A Word of Caution.
70  compared to clinical therapeutic exposure levels
(1 time)
Toxicology
(1 time)
LEC (1 time)
2019 A murine ex vivo 3D kidney proximal tubule model predicts clinical drug-induced nephrotoxicity.
71  Compared to free lutein, PLGA-NP increased the maximal plasma concentration
(1 time)
Chemistry
(1 time)
NP (1 time)
PLGA (1 time)
2016 Bioavailability and biodistribution of nanodelivered lutein.
72  Compared to the fat-free trial, plasma quercetin maximum concentration
(1 time)
Nutritional Sciences
(1 time)
CVD (1 time)
2013 Dietary fat increases quercetin bioavailability in overweight adults.
73  Compared with oral administration, maximum plasma concentration
(1 time)
Pharmacology
(1 time)
AUC (1 time)
DGME (1 time)
PGML (1 time)
2008 Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
74  compared with placebo, and maximum plasma concentration
(1 time)
Neurology
(1 time)
COMT (1 time)
tmax (1 time)
1997 The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
75  Compared with the XF group, the maximum plasma concentration
(1 time)
Chemistry Techniques, Analytical
(1 time)
SXF (1 time)
XF (1 time)
2019 Ultra-high-performance liquid chromatography with tandem mass spectrometry method for determination of four compounds in rat plasma after oral administration of Xanthii fructus and stir-fried Xanthii fructus extracts.
76  compared with volunteers, respectively, were as follows: maximum concentration
(1 time)
Anti-Bacterial Agents
(1 time)
AUCt (1 time)
DFI (1 time)
SD (1 time)
2018 Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis.
77  Comparison of the available studies showed lower maximum concentrations
(1 time)
Tropical Medicine
(1 time)
ACT (1 time)
2016 The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review.
78  comparison to water, maximum ABZSX concentration
(1 time)
Tropical Medicine
(1 time)
ABZSX (1 time)
2002 Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability.
79  comparisons, and factors such as the maximum drug concentration
(1 time)
Pharmacology
(1 time)
AUC (1 time)
2018 Finding Tmax and Cmax in Multicompartmental Models.
80  complete absorption, with a mean maximal plasma concentration
(1 time)
Veterinary Medicine
(1 time)
AUCinf (1 time)
i.v (1 time)
s.c (1 time)
2014 Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs.
81  complex was reflected in the maximum plasma level
(1 time)
Pharmacology
(1 time)
gamma-CyD (1 time)
2016 The formation of an inclusion complex between a metabolite of ginsenoside, compound K and gamma-cyclodextrin and its dissolution characteristics.
82  computed variables: the maximum plasma concentration
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
SID (1 time)
tmax (1 time)
ZDV (1 time)
1996 Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease.
83  concentration (AUC(0-t)) or maximum concentration
(1 time)
Drug Therapy
(1 time)
--- 1997 Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
84  concentration maximum in plasma
(1 time)
Drug Therapy
(1 time)
AUC (1 time)
1991 The influence of food on the absorption of diclofenac as a pure substance.
85  concentration of morphine extrapolated to time zero
(1 time)
Pharmacology
(1 time)
MRT (1 time)
1991 Tolerance-dependence and serum elimination of morphine in rats implanted with morphine pellets.
86  concentration of ofloxacin in serum
(1 time)
Anti-Bacterial Agents
(1 time)
CI (1 time)
1996 Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.
87  concentration of roxithromycin
(1 time)
Pharmacology
(1 time)
--- 1989 Pharmacokinetics of a new macrolide, roxithromycin, in infants and children.
88  concentration reached its maximum
(1 time)
Environmental Health
(1 time)
ES (1 time)
GI (1 time)
OC (1 time)
2005 Toxicokinetics of 14C-endosulfan in male Sprague-Dawley rats following oral administration of single or repeated doses.
89  concentration reached maximum level
(1 time)
Gastroenterology
(1 time)
CH (1 time)
LC (1 time)
1990 Vitamin K (menaquinone-4) metabolism in liver disease.
90  concentration showed a maximum
(1 time)
Communicable Diseases
(1 time)
--- 2007 Pharmacokinetics and tissue residues of an oxytetracycline/diclofenac combination in cattle.
91  concentration time curves (AUC(0-last)) and peak concentration of cefuroxime
(1 time)
Pathology
(1 time)
IAO (1 time)
PIBA (1 time)
2017 Suppurative Inflammation and Local Tissue Destruction Reduce the Penetration of Cefuroxime to Infected Bone Implant Cavities.
92  concentration versus time (AUC(0-tau)), maximum concentration
(1 time)
Pharmacology
(1 time)
CBTL (1 time)
CBZ (1 time)
CBZ-E (1 time)
1998 Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).
93  concentration was expressed as maximal
(1 time)
Pulmonary Medicine
(1 time)
CFCs (1 time)
DPI (1 time)
MDI (1 time)
1997 Lung delivery of salbutamol by dry powder inhaler (Turbuhaler) and small volume antistatic metal spacer (Airomir CFC-free MDI plus NebuChamber).
94  concentration, AUC extrapolated to infinity, maximum concentration
(1 time)
Gastroenterology
(1 time)
AEs (1 time)
AUC (1 time)
GLP (1 time)
2014 A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.
95  concentrations associated with maximum antinociceptive effect
(1 time)
Veterinary Medicine
(1 time)
Tmax (1 time)
TT (1 time)
2016 Pharmacokinetic and pharmacodynamic evaluation of high doses of buprenorphine delivered via high-concentration formulations in cats.
96  concentrations attained a maximum
(1 time)
Laboratory Techniques and Procedures
(1 time)
i.n (1 time)
i.v (1 time)
2000 Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination.
97  concentrations normalized to maximal therapeutic blood levels
(1 time)
Toxicology
(1 time)
KI (1 time)
2018 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.
98  concentrations of moxifloxacin in plasma
(1 time)
Anti-Bacterial Agents
(1 time)
AUC (1 time)
1998 Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.
99  concentrations of nefiracetam reached maximum values
(1 time)
Pharmacology
(1 time)
CL (1 time)
CLR (1 time)
1992 Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers.
100  concentrations of norfluoxetine, in terms of maximum concentrations
(1 time)
Pharmacology
(1 time)
5-HT (1 time)
AUC (1 time)
1992 Anorectic activity of fluoxetine and norfluoxetine in rats: relationship between brain concentrations and in-vitro potencies on monoaminergic mechanisms.